Pay in 4 interest-free payments of $6.21 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Related research, protocols, and guides Explore the available research context, protocol variants or comparisons, and practical guides
Phase 1a: First-in-Human Single Ascending Dose Study (NCT02951806) Study Title: "Safety, Tolerability, and Pharmacokinetics of Single Doses of Cagrilintide in Healthy Subjects" Status: Completed Phase: Phase 1a Enrollment: 48 healthy volunteers Study Period: 2016-2017 Location: Single center (Denmark) Design: Randomized, double-blind, placebo-controlled, single ascending dose Dose Range: 0.03-10 mg SC Primary Endpoints: Safety, tolerability, PK parameters Population: Healthy male subjects, BMI 20-28 Key Results: Pharmacokinetics: Terminal half-life 5-7 days across dose range
Recently, interest in TMAO has extended beyond the world of marine biology, with a growing body of research linking it to cardiovascular disease (CVD), insulin resistance, renal dysfunction, cancer, stroke, and inflammation in humans (Velasquez et al
Read the current Terms before submitting payment
